Welcome to our Free Content Page
The Medical Letter, Inc. is a nonprofit organization--we accept no grants, donations or advertising. We are supported entirely by sales of our subscriptions, handbooks and software. If you value the balanced truth, and wish to ensure your continued access to this impartial source of drug information, please subscribe today.   
The Medical Letter on Drugs and Therapeutics • September 8, 2008 (Issue 1294)
Sunscreens are an important component of photoprotection. A new definition of their effectiveness has been proposed, and some issues have arisen concerning their safety.

Click here to view the free full article.
The Medical Letter on Drugs and Therapeutics • November 19, 2007 (Issue 1274)
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer. Clinically important BRCA mutations have been found in about 2% of Ashkenazi Jewish women, and are estimated to occur in about 1 in 300 to 500 women in the general non-Jewish US...
The Medical Letter on Drugs and Therapeutics • December 5, 2005 (Issue 1223)
Many patients planning to travel seek advice about prevention of malaria. No drug is 100% effective for this indication; travelers should be told to take other protective measures as well. Malaria in pregnancy is particularly serious for both mother and fetus; prophylaxis is indicated if travel cannot be avoided. Countries with a risk of malaria are listed in the table on page 102. Some countries...
The Medical Letter on Drugs and Therapeutics • June 6, 2005 (Issue 1210)
Picaridin (KBR 3023), which has been used as an insect repellent for years in Europe and Australia (Autan Repel, and others), is now available in the US in 7% solution as Cutter Advanced (Spectrum Brands). The US Centers for Disease Control and Prevention (CDC) is recommending it as an alternative to DEET.

...
The Medical Letter on Drugs and Therapeutics • June 7, 2004 (Issue 1184)
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part...
The Medical Letter on Drugs and Therapeutics • December 8, 2003 (Issue 1171)
Questions have been raised in the US press recently about the safety of Canadian drugs. The process of drug approval in Canada is similar to that in the US (D Paul, Int J Med Marketing 2001; 1:224). More than 90% of drugs available in Canada have also been approved by the FDA. Most of these drugs come from the same manufacturers as drugs in the US. Health Canada takes longer on average to release...